[A16-05] Dabrafenib/trametinib - Addendum to Commissions A15-39 and A15-40
Last updated 17.03.2016
Project no.:
A16-05
Commission:
Commission awarded on 09.02.2016 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Skin and hair
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently on the extent of the added benefit, thus completing the early benefit assessment: decides-dabrafenib / decides-trametinib
| Project no. | Title | Status |
|---|---|---|
| A15-39 | Dabrafenib (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A15-40 | Trametinib - Benefit assessment according to §35a Social Code Book V (dossier assessment) | Commission completed |
Federal Joint Committee (G-BA)
2016-03-17 A G-BA decision was published on trametinib.
G-BA documents on this decision
2016-03-17 A G-BA decision was published on dabrafenib.